Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs 10X Genomics Inc (TXG) Price & Performance

Hewlett Packard Enterprise CoTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs 10X Genomics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $56.99 (market cap $72.01B), while 10X Genomics Inc trades at $57.29 (market cap $7.61B). The key difference: Hewlett Packard Enterprise Co is far larger — about 9.5× 10X Genomics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

HPETXG
Market Cap
$72.01B$7.61B
Sector
TechnologyHealth
52-Week High
$56.14$58.57
52-Week Low
$20.01$11.34
Enterprise Value
$87.96B$7.14B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE stock trades at $56.32, up 3.02% with strong momentum following recent analyst upgrades. The company shows robust earnings beats in recent quarters with Q1 2026 EPS of $0.79 beating expectations of $0.535. Technical indicators suggest bullish momentum while fundamentals show revenue growth to $34.3B in 2025, though net income declined significantly to $57M. Recent Morgan Stanley upgrade highlights AI infrastructure strength.

Outlook remains positive with AI-driven growth potential, though elevated P/E ratio of 50.82 warrants caution. Key risks include competitive pressures in server markets and execution challenges. Analyst consensus price target of $69.81 offers 24% upside potential from current levels, supported by institutional buying interest.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG